Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Income towards Parent Company: 2019-2023

Historic Income towards Parent Company for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Income towards Parent Company fell 189.52% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 216.62%. This contributed to the annual value of -$155,800 for FY2022, which is 32.27% up from last year.
  • Per ADC Therapeutics' latest filing, its Income towards Parent Company stood at -$45.3 million for Q3 2023, which was up 6.01% from -$48.2 million recorded in Q2 2023.
  • ADC Therapeutics' Income towards Parent Company's 5-year high stood at $126.6 million during Q2 2020, with a 5-year trough of -$60.0 million in Q1 2023.
  • Over the past 3 years, ADC Therapeutics' median Income towards Parent Company value was $16.7 million (recorded in 2022), while the average stood at $15.8 million.
  • As far as peak fluctuations go, ADC Therapeutics' Income towards Parent Company soared by 477,493.44% in 2020, and later crashed by 459.82% in 2023.
  • Over the past 5 years, ADC Therapeutics' Income towards Parent Company (Quarterly) stood at -$35,285 in 2019, then skyrocketed by 64,960.73% to $20.3 million in 2020, then spiked by 251.97% to -$34,381 in 2021, then grew by 29.74% to -$24,157 in 2022, then slumped by 189.52% to -$45.3 million in 2023.
  • Its Income towards Parent Company was -$45.3 million in Q3 2023, compared to -$48.2 million in Q2 2023 and -$60.0 million in Q1 2023.